Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Equivalents (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Cash & Equivalents for 14 consecutive years, with $44.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash & Equivalents rose 25.26% year-over-year to $44.8 million, compared with a TTM value of $44.8 million through Jun 2025, up 25.26%, and an annual FY2024 reading of $37.2 million, down 56.4% over the prior year.
  • Cash & Equivalents was $44.8 million for Q2 2025 at Enanta Pharmaceuticals, down from $84.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $85.4 million in Q3 2023 and bottomed at $28.4 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $54.6 million, with a median of $44.4 million recorded in 2022.
  • Peak annual rise in Cash & Equivalents hit 111.23% in 2024, while the deepest fall reached 56.4% in 2024.
  • Year by year, Cash & Equivalents stood at $77.1 million in 2021, then plummeted by 42.96% to $44.0 million in 2022, then decreased by 9.23% to $39.9 million in 2023, then surged by 111.23% to $84.3 million in 2024, then plummeted by 46.87% to $44.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for ENTA at $44.8 million in Q2 2025, $84.3 million in Q4 2024, and $37.2 million in Q3 2024.